Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pitavastatin Added to JAK Inhibitors in Myelofibrosis (Phase II)
jRCT2071260059Phase 2Not yet recruiting
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pitavastatin in myelofibrosis (MF), sponsored by none. Primary endpoint: Reduction in bone marrow fibrosis grade at Week 36. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
pitavastatin
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on jRCT2071260059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260059.